Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular Carcinoma
Interventionnel
Phase 2
West China Hospital of Sichuan University
Sponsor: Zelgen Biopharmaceuticals
Dernière synchronisation : 25 mars 2025 Avis - Les informations proviennent de registres publics et peuvent ne pas refléter les changements en temps réel sur le site local.
This study is a randomized, open-label, positive-controlled, multicenter phase II clinical trial. It evaluates the efficacy and safety of ZG005 combined with Bevacizumab compared to Sintilimab combined with Bevacizumab in first-line treatment for patients with advanced hepatocellular carcinoma.
Catégorie de traitement
Autres médicaments, Anticorps monoclonaux, Inhibiteurs de points de contrôle